ABT-436

ABT-436 is an orally active, highly selective vasopressin V1B receptor antagonist which was under development by Abbott Laboratories and AbbVie for the treatment of major depressive disorder, anxiety disorders, and alcoholism but was discontinued.[1][2][3] It reached phase II clinical trials prior to the discontinuation of its development.[1][3]

ABT-436
Clinical data
Routes of
administration		By mouth
Identifiers
CAS Number

See also

References
  1. "ABT 436". AdisInsight. Springer Nature Switzerland AG.
  2. Wernet W, Hornberger WB, Unger LV, Meyer AH, Netz PA, Oost T, et al. (2008). In vitro characterization of the selective vasopressin V1b receptor antagonists ABT-436 and ABT-558. Proceedings of Society for Neuroscience. Washington DC, USA. p. Abstract 560.
  3. Ryan ML, Falk DE, Fertig JB, Rendenbach-Mueller B, Katz DA, Tracy KA, et al. (April 2017). "A Phase 2, Double-Blind, Placebo-Controlled Randomized Trial Assessing the Efficacy of ABT-436, a Novel V1b Receptor Antagonist, for Alcohol Dependence". Neuropsychopharmacology. 42 (5): 1012–1023. doi:10.1038/npp.2016.214. PMC 5506792. PMID 27658483.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.